A detailed history of Vanguard Group Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,700,007 shares of RARE stock, worth $358 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,700,007
Previous 8,673,432 0.31%
Holding current value
$358 Million
Previous $415 Million 2.06%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$43.02 - $53.69 $1.14 Million - $1.43 Million
26,575 Added 0.31%
8,700,007 $406 Million
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $45.7 Million - $70.8 Million
1,440,264 Added 19.91%
8,673,432 $415 Million
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $7.5 Million - $10 Million
214,666 Added 3.06%
7,233,168 $258 Million
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $9.9 Million - $13.8 Million
265,175 Added 3.93%
7,018,502 $324 Million
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $14 Million - $18.5 Million
379,097 Added 5.95%
6,753,327 $271 Million
Q4 2022

Feb 10, 2023

BUY
$33.72 - $46.33 $7.16 Million - $9.84 Million
212,364 Added 3.45%
6,374,230 $295 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $1.11 Million - $1.83 Million
27,722 Added 0.45%
6,161,866 $255 Million
Q2 2022

Aug 12, 2022

BUY
$45.8 - $85.4 $7.82 Million - $14.6 Million
170,770 Added 2.86%
6,134,144 $366 Million
Q1 2022

May 13, 2022

BUY
$62.2 - $84.4 $2.66 Million - $3.61 Million
42,806 Added 0.72%
5,963,374 $433 Million
Q4 2021

Feb 14, 2022

BUY
$73.71 - $87.86 $3.37 Million - $4.02 Million
45,737 Added 0.78%
5,920,568 $498 Million
Q3 2021

Nov 12, 2021

BUY
$77.92 - $102.4 $16.2 Million - $21.3 Million
208,494 Added 3.68%
5,874,831 $530 Million
Q2 2021

Aug 13, 2021

BUY
$92.19 - $115.71 $522 Million - $656 Million
5,666,337 New
5,666,337 $540 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.88B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.